Unknown

Dataset Information

0

Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.


ABSTRACT: Bleeding risk represents a major concern in anticoagulated patients with atrial fibrillation (AF). Several bleeding prediction scores have been described: HAS-BLED, ATRIA, HEMORR2HAGES and ORBIT. Of these, only HAS-BLED considers quality of anticoagulation control amongst vitamin K antagonist (VKA) users. We hypothesised that predictive value of bleeding risk scores other than HAS-BLED could be improved incorporating time in therapeutic range (TTR) in warfarin-treated patients. Of the 127 adjudicated major bleeding events, 21.3% of events occurred in 'low-risk' HAS-BLED category (1.8 per 100 patient-years), compared to higher proportions (?50% of events; ~2.5 per 100 patient-years) in 'low-risk' categories for other scores. Only the 'low-risk' HAS-BLED category was associated with the absence of investigator-defined major bleeding events (OR: 1.46;95% CI: 1.00-2.15). 'High' or 'medium/high' risk categories for the HAS-BLED (p?=?0.023) or ORBIT (p?=?0.022) scores, respectively, conferred significant risk for adjudicated major bleeding events. On Cox regression analysis, adjudicated major bleeding was associated only with HAS-BLED (HR: 1.62;95% CI: 1.06-2.48) and ORBIT (HR: 1.83;95% CI: 1.08-3.09) 'high-risk' categories. Adding 'labile INR' (TTR?

SUBMITTER: Proietti M 

PROVIDER: S-EPMC4828703 | biostudies-other | 2016 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.

Proietti Marco M   Senoo Keitaro K   Lane Deirdre A DA   Lip Gregory Y H GY  

Scientific reports 20160412


Bleeding risk represents a major concern in anticoagulated patients with atrial fibrillation (AF). Several bleeding prediction scores have been described: HAS-BLED, ATRIA, HEMORR2HAGES and ORBIT. Of these, only HAS-BLED considers quality of anticoagulation control amongst vitamin K antagonist (VKA) users. We hypothesised that predictive value of bleeding risk scores other than HAS-BLED could be improved incorporating time in therapeutic range (TTR) in warfarin-treated patients. Of the 127 adjudi  ...[more]

Similar Datasets

| S-EPMC5608893 | biostudies-other
| S-EPMC5523754 | biostudies-other
| S-EPMC7989114 | biostudies-literature
| S-EPMC7118015 | biostudies-literature
| S-EPMC9299168 | biostudies-literature
| S-EPMC4919727 | biostudies-literature
| S-EPMC6220555 | biostudies-literature
| S-EPMC6794239 | biostudies-literature
| S-EPMC5342334 | biostudies-literature
| S-EPMC10164915 | biostudies-literature